Format

Send to

Choose Destination

Links from PubChem BioAssay

See comment in PubMed Commons below
J Med Chem. 2013 Apr 11;56(7):2705-25. doi: 10.1021/jm301557k. Epub 2013 Mar 11.

Pharmacological chaperones as therapeutics for lysosomal storage diseases.

Author information

  • 1Amicus Therapeutics, 1 Cedar Brook Drive, Cranbury, New Jersey 08512, United States. rboyd@amicusrx.com

Abstract

Lysosomal enzymes are responsible for the degradation of a wide variety of glycolipids, oligosaccharides, proteins, and glycoproteins. Inherited mutations in the genes that encode these proteins can lead to reduced stability of newly synthesized lysosomal enzymes. While often catalytically competent, the mutated enzymes are unable to efficiently pass the quality control mechanisms of the endoplasmic reticulum, resulting in reduced lysosomal trafficking, substrate accumulation, and cellular dysfunction. Pharmacological chaperones (PCs) are small molecules that bind and stabilize mutant lysosomal enzymes, thereby allowing proper cellular translocation. Such compounds have been shown to increase enzyme activity and reduce substrate burden in a number of preclinical models and clinical studies. In this Perspective, we review several of the lysosomal diseases for which PCs have been studied and the SAR of the various classes of molecules.

PMID:
23363020
DOI:
10.1021/jm301557k
[PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Other Literature Sources

Chemical Information

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Chemical Society
    Loading ...
    Support Center